A carregar...
Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase
BACKGROUND: Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail. METHODS: Here, we...
Na minha lista:
Main Authors: | , , , , , , , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BioMed Central
2010
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3019212/ https://ncbi.nlm.nih.gov/pubmed/21144000 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-10-677 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|